A Study of Niraparib in Patients With Relapsed Ovarian Cancer

NCT ID: NCT04392102

Last Updated: 2022-08-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-04
• Study Completion Date: 2022-08-11

Brief Summary

This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy regimens. Niraparib is an orally active PARP inhibitor. Niraparib will be administered once daily continuously during a 28-day cycle. Health-related quality of life will be measured by Eastern Cooperative Oncology Group performance status (ECOG). Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), RECIST tumor assessments and safety laboratory values.

Conditions

Ovarian Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ZL-2306(Niraparib)

The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count

Group Type: EXPERIMENTAL

ZL-2306(Niraparib）

Intervention Type: DRUG

The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count

Interventions

ZL-2306(Niraparib）

The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count

Intervention Type: DRUG

Other Intervention Names

Zejula

Eligibility Criteria

Inclusion Criteria

• 1. Patients must be female and at least 18 years of age
• 2. Patients must provide written informed consent
• 3. Patients must be gBRCA mutation or HRD positive
• 4. Patients must have histologically diagnosed high-grade (Grade 2 or 3)serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent disease.
• 5. Patients Must have completed 3 or 4 previous chemotherapy regimens.
• 6. Patients must have measurable disease according to RECIST (v.1.1).
• 7. Patients must have an Eastern Cooperative Oncology Group(ECOG) performance status of 0 or1
• 8. Patients must have adequate organ function, defined as follows: a. Absolute neutrophil count≥1500/ul b. Platelets ≥150000/ul c. Hemoglobin≥10g/dL d. Serum creatinine≤1.5X upper limit of normal (ULN)or calculated creatinine clearance≥60ml/min using the Cockcroft-Gault equation e. Total bilirubin≤1.5X ULN OR direct bilirubin≤1X ULN f. Aspartate aminotransferase and alanine aminotransferase≤2.5X ULN unless liver metastases are present, in which case they must be ≤5X ULN
• 9. Patients must be either postmenopausal, free from menses for>12 months, surgically sterilized, or willing to use adequate contraception to prevent pregnancy or must agree to abstain from heterosexual activity throughout the study, starting with enrollment through 90 days after the last dose of study treatment
• 10. Patients must have formalin-fixed, paraffin-embedded tumor samples available form primary or recurrent cancer.
• 11. Patients must be able to take oral medications and capable of complying with treatment and follow up visit

Exclusion Criteria

• 1. Patients who have received other investigational drugs within 4 weeks or 5X t1/2 before first dose of study treatment.
• 2. Patients have had palliative radiotherapy encompassing>20% of the bone marrow within 3 weeks of the first dose of study treatment.
• 3. Patients have any known, persistent(>4 weeks)，≥Grade 3 anemia, neutrophil count decrease or platelet count decrease during the last chemotherapy.
• 4. Patients have any known, persistent (>4 weeks), ≥ Grade 3 fatigue during the last chemotherapy.
• 5. Patients have received pelvic radiotherapy as treatment for primary or recurrent disease within 1 year of the first dose of study treatment.
• 6. Patients have symptomatic uncontrolled brain or leptomeningeal metastases. The patient have new or progressive signs or symptoms related to the CNS disease and not taking a stable dose of steroids or no steroids. A scan to confirm the absence of brain metastases is not required.
• 7. Patients have known hypersensitivity to the components of niraparib
• 8. Patient have had major surgery within 3 weeks of fist dose treatment and patient must have recovered form any effects of any major surgery
• 9. Patients have had diagnosis, detection, or treatment of invasive cancer other than ovarian cancer ≤2 years prior to enrollment(except basal or squamous cell carcinoma of the skin that has been definitively treated)
• 10. Patients are considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to: 1. uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction 2. uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome or any psychiatric disorder that prohibits obtaining informed consent 3. immune deficiency (not including splenectomy) 4. HIV infection or active hepatitis(i.e. hepatitis B with HBV-DNA>500IU/ml or hepatitis C with positive HCV-RNA).
• 11. Patients have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment.
• 12. Patients have known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
• 13. Patients have current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study or interfere with patient's participation for the full duration of the study treatment or that makes it not in the best interest of the patient to participate

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Zai Lab (Shanghai) Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rutie Yin

Role: PRINCIPAL_INVESTIGATOR

West China Second University Hospital

Xiaohua Wu

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Hong Zheng

Role: PRINCIPAL_INVESTIGATOR

Peking University Cancer Hospital & Institute

Ge Lou

Role: PRINCIPAL_INVESTIGATOR

Harbin Medical University

Lingying Wu

Role: PRINCIPAL_INVESTIGATOR

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Hongmin Pan

Role: PRINCIPAL_INVESTIGATOR

Sir Run Shaw Hospital, school of medicine, Zhejiang University

Zhongqiu Lin

Role: PRINCIPAL_INVESTIGATOR

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Sun Yat-sen Memorial Hospital,Sun Yat-sen University

Guangzhou, Guangdong, China

Harbin Medical University

Haerbin, Heilongjiang, China

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

West China Second Iniversity Hospital

Chengdu, Sichuan, China

Sir Run Shaw Hospital, school of medicine, Zhejiang University

Guangzhou, Zhejiang, China

Countries

China

Other Identifiers

ZL-2306-008

Identifier Type: -

Identifier Source: org_study_id